Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report
- Authors:
- Published online on: March 30, 2015 https://doi.org/10.3892/mco.2015.531
- Pages: 889-891
Metrics:
Total
Views: 0 (Spandidos Publications: | PMC Statistics:
)
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics:
)
Abstract
Therapy with crizotinib achieves prolonged progression-free and overall survival in non-small-cell lung cancer (NSCLC) patients with echinoderm microtubule‑associated protein‑like 4 (EML4)‑anaplastic lymphoma kinase (ALK). It was demonstrated that ALK‑positive NSCLCs exhibit a high response rate to the ALK inhibitor, crizotinib. However, a proportion of the patients discontinue crizotinib treatment due to adverse events. This is the case report of a NSCLC patient with EML4‑ALK rearrangement, who, following crizotinib discontinuation for one year due to adverse events, exhibited a marked response to alectinib. Even if the incidence is not high, clinicians should not overlook the most common crizotinib‑related adverse events. Furthermore, certain patients may continue to benefit from alectinib following long‑term discontinuation of crizotinib therapy.
